Læknablaðið - 15.07.2009, Blaðsíða 26

FRÆÐIGREINAR
Y F I R L I T
5. Landlæknisembættið. Tilkynningaskyldir sjúkdómar.
Reykjavík: Landlæknisembættið, 2008. Sjá www.landlaeknir.
is/Pages/876
6. World Health Organisation. TB country profile: Iceland.
Geneva: World Health Organisation, 2008. Sjá www.who.
int/globalatlas/predefinedReports/TB/index.asp?strSelect
edCountry=ISL
7. World Health Organisation. Guidelines for the programmatic
management of drug-resistant tuberculosis: Emergency
update 2008. WHO/HTM/TB/2008.402. Geneva: World
Health Organisation, 2008.
8. Centers for Disease Control and Prevention (CDC). Revised
definition of extensively drug-resistant tuberculosis. MMWR
Morb Mortal Wkly Rep 2006; 55:1176.
9. World Health Organisation. Anti-tuberculosis drug
resistance in the world. Fourth global report. WHO/HTM/
TB/2008.394. Geneva: World Health Organisation, 2008.
10. Centers for Disease Control and Prevention (CDC).
Emergence of Mycobacterium tuberculosis with extensive
resistance to second-line drugs—worldwide, 2000-2004.
MMWR Morb Mortal Wkly Rep 2006; 55: 301-5.
11. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of
extensively drug-resistant tuberculosis. Emerg Infect Dis
2007;13: 380-7.
12. World Health Organisation. Global map and information
on XDR-TB. Geneva: World Health Organization, 2009. Sjá
www.who.int/tb/challenges/xdr/xdr_map_feb09.pdf
13. Centers for Disease Control and Prevention (CDC).
Extensively drug-resistant tuberculosis—United States, 1993-
2006. MMWR Morb Mortal Wkly Rep 2007; 56: 250-3.
14. Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-
resistant tuberculosis, Italy and Germany. Emerg Infect Dis
2007;13: 780-2.
15. Chan ED, Laurel V, Strand MJ, et al. Treatment and
outcome analysis of 205 patients with multidrug-resistant
tuberculosis. Am J Respir Crit Care Med 2004; 169:1103-9.
16. Yew WW, Leung CC. Management of multidrug-resistant
tuberculosis: Update 2007. Respirology 2008; 13: 21-46.
17. Kim DH, Kim HJ, Park SK, et al. Treatment Outcomes and
Long-term Survival in Patients with Extensively Drug-
resistant Tuberculosis. Am J Respir Crit Care Med 2008; 178:
1075-82.
18. Kwon YS, Kim YH, Suh GY, et al. Treatment outcomes
for HlV-uninfected patients with multidrug-resistant and
extensively drug-resistant tuberculosis. Clin Infect Dis 2008;
47: 496-502.
19. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive
treatment of extensively drug-resistant tuberculosis. N Engl
J Med 2008; 359: 563-74.
20. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-
resistant tuberculosis as a cause of death in patients co-
infected with tuberculosis and HIV in a rural area of South
Africa. Lancet 2006; 368:1575-80.
21. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of
extensively drug-resistant tuberculosis in Tomsk, Russia: a
retrospective cohort study. Lancet 2008; 372:1403-9.
22. Ollé-Goig JE. Editorial: the treatment of multi-drug resistant
tuberculosis—a return to the pre-antibiotic era? Trop Med Int
Health 2006; 11:1625-8.
23. Crofton J, Mitchinson DA. Streptomycin resistance in
pulmonary tuberculosis. Br Med J1948; 2:1009-15.
24. Mitchison DA. How drug resistance emerges as a result
of poor compliance during short course chemotherapy for
tuberculosis. Int J Tuberc Lung Dis 1998; 2:10-5.
25. Blumberg HM, Burman WJ, Chaisson RE, et al. American
Thoracic Society/Centers for Disease Control and
Prevention/Infectious Diseases Society of America:
treatment of tuberculosis. Am J Respir Crit Care Med 2003;
167: 603-62.
26. Pomerantz BJ, Cleveland JC, Olson HK, Pomerantz M.
Pulmonary resection for multi-drug resistant tuberculosis. J
Thorac Cardiovasc Surg 2001; 121: 448-53.
27. Telenti A, Honoré N, Bemasconi C, et al. Genotypic
assessment of isoniazid and rifampin resistance in
Mycobacterium tuberculosis: a blind study at reference
laboratory level. J Clin Microbiol 1997; 35: 719-23.
28. O'Riordan P, Schwab U, Logan S, et al. Rapid molecular
detection of rifampicin resistance facilitates early diagnosis
and treatment of multi-dmg resistant tuberculosis: case
control study. PLoS ONE 2008; 3:e3173.
29. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ.
Vitamin D in the treatment of pulmonary tuberculosis. J
Steroid Biochem Mol Biol 2007; 103: 793-8.
30. Ralph AP, Kelly PM, Anstey NM. Trends Microbiol. L-
arginine and vitamin D: novel adjunctive immunotherapies
in tuberculosis 2008; 16: 336-44.
31. Ntziora F, Falagas ME. Linezolid for the treatment of
patients with [leiðrétt] mycobacterial infections [leiðrétt]: a
systematic review. Int J Tuberc Lung Dis 2007; 11: 606-11.
32. Nam HS, Koh WJ, Kwon OJ, Cho SN, Shim TS. Daily half-
dose linezolid for the treatment of intractable multidrug-
resistant tuberculosis. Int J Antimicrob Agents 2009; 33:
92-3.
33. Nathanson E, Gupta R, Huamani P, et al. Adverse events
in the treatment of multidrug-resistant tuberculosis: results
from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8:
1382-4.
34. Breen RA, Miller RF, Gorsuch T, et al. Adverse events and
treatment intermption in tuberculosis patients with and
without HIV co-infection. Thorax 2006; 61: 791-4.
35. Taylor Z, Nolan CM, Blumberg HM, American Thoracic
Society; Centers for Disease Control and Prevention;
Infectious Diseases Society of America. Controlling
tuberculosis in the United States. Recommendations from
the American Thoracic Society, CDC, and the Infectious
Diseases Society of America. MMWR Recomm Rep 2005; 54:
1-81.
36. Horsburgh CR. Priorities for the treatment of latent
tuberculosis infection in the United States. N Engl J Med
2004; 350: 2060-7.
37. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid
for preventing tuberculosis in non-HIV infected persons.
Cochrane Database Syst Rev 2000; 2: CD001363.
38. Fraser A, Paul M, Attamna A, Leibovici L. Treatment of
latent tuberculosis in persons at risk for multidmg-resistant
tuberculosis: systematic review. Int J Tuberc Lung Dis 2006;
10:19-23.
39. Fraser A, Paul M, Attamna A, Leibovici L. Drugs for
preventing tuberculosis in people at risk of multiple-dmg-
resistant pulmonary tuberculosis. Cochrane Database Syst
Rev 2006; 2: CD005435.
40. Feja K, McNelley E, Tran CS, Burzynski J, Saiman L.
Management of pediatric multidmg-resistant tuberculosis
and latent tuberculosis infections in New York City from
1995 to 2003. Pediatr Infect Dis J 2008; 27: 907-12.
41. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB,
Donald PR. Evaluation of young children in contact with
adult multidrug-resistant pulmonary tuberculosis: a 30-
month follow-up. Pediatrics 2002; 109: 765-71.
42. Coker RJ, Mounier-Jack S, Martin R. Public health law and
tuberculosis control in Europe. Public Health 2007; 121: 266-
73.
43. Verklagsreglur um læknisrannsókn. Landlæknisembættið,
Reykjavík 2007. Sjá www.landlaeknir.is/pages/898
506 LÆKNAblaðið 2009/95